Sanofi appoints chief strategy officer

To cover all group business development activities

Sanofi has appointed Dr David-Alexandre Gros as chief strategy officer. He takes over the role on 1 September, reporting to chief executive Christopher Viehbacher. He will also join the group executive committee and be based in Paris, France.

Gros’ role will cover all group business development and acquisition activities, plus strategic planning, economic evaluation of projects, strategic intelligence, and alliance management.

Gros joins Sanofi after serving as an advisor to pharmaceutical, biotechnology and diagnostic companies as a principal and founding member of the Healthcare Investment Banking division at Centerview Partners, in San Francisco, CA.

He holds a BA from Dartmouth College (1995), an MD from Johns Hopkins University School of Medicine (1999), and an MBA from Harvard Business School (2002).

You may also like

Finance

Sanofi completes acquisition of Blueprint Medicines

Sanofi announces the completion of its acquisition of Blueprint Medicines Corporation, adding to its portfolio a commercialised medicine and the expertise of a company specialising in systemic mastocytosis (SM) and other KIT-driven diseases
Distribution

Sanofi ramps up Beyfortus shipping ahead of '25–26 RSV season

Sanofi will boost the availability of the RSV monoclonal antibody vaccine across the US, EU, China and Japan to protect infants from the disease
Research & Development

Sanofi to acquire immunology-focused biopharma company, Blueprint Medicines

The acquisition will allow Sanofi access to Blueprint's rare immunology disease pipeline — a current key focus for the company
Finance

Sanofi completes acquisition of DR-0201

The acquisition bolsters Sanofi’s ambition to become the foremost immunology company and broadens the company’s leading immunology pipeline
Research & Development

Sanofi to acquire neurodegenerative disease biotech, Vigil Neuroscience for $470m

The acquisition will boost Sanofi's neurology pipeline — one of its key disease focus areas
Manufacturing

Sanofi to invest $20bn into US manufacturing capacity following Trump's tariff threats

The company will expand its US pharmaceutical R&D and manufacturing capacity through internal and contract manufacturing investments
Regulatory

Sanofi's BTK inhibitor rilzabrutinib granted FDA orphan drug designation

Rilzabrutinib has already received orphan drug designation from the EU and Japan for use in patients with immune thrombocytopenia
Subscribe now